
Core Points - A lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) for alleged violations of securities laws related to its IPO and subsequent statements [3] - Investors who purchased over $100,000 in shares between February 2, 2024, and October 22, 2024, have a deadline of September 19, 2025, to take action [2] - The lawsuit claims that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated, leading to misleading public statements about the company's financial and business prospects [3] Company Information - Alto Neuroscience, Inc. is facing legal scrutiny due to allegations that its IPO documents contained false or misleading information regarding its product's effectiveness [3] - The Shareholders Foundation, Inc. is facilitating communication for affected investors and provides services related to shareholder issues and securities class actions [4]